Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Trial Profile

Phase I-II Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Dacarbazine (Primary) ; Doxorubicin (Primary) ; Ifosfamide (Primary) ; Methotrexate (Primary) ; Nivolumab (Primary) ; Sunitinib (Primary)
  • Indications Alveolar soft part sarcoma; Bone cancer; Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ImmunoSarc
  • Most Recent Events

    • 04 Jun 2024 Results ( N=24) assessing safety and efficacy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 24 Oct 2023 Results (n=26; from Oct. 2019 to Apr. 2023) assessing the efficacy and safety of sunitinib and nivolumab in vascular sarcomas cohort, presented at the 48th European Society for Medical Oncology Congress.
    • 06 Jun 2023 Results (n=20 of phase Ib, cohort 7b) hypothesizing that the addition of an anti-PD1 (nivolumab) would increase the antitumor activity of commonly used upfront polychemotherapy in leiomyosarcoma of doxorubicin plus dacarbazine presented at the 59th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top